Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

By sjmartinez • January 27, 2023

Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023 Jan 23:S2213-2600(22)00492-1. doi: 10.1016/S2213-2600(22)00492-1. Epub ahead of print. PMID: 36702146.

Tags: clinical immunology and allergy, Publications

Drug Development

Cole GM, Zhu C, Manglani K, Hou K, Bombino A, Jones M, Eisenberg DS, Frautschy SA. Drug Development. Alzheimers Dement. 2025 Dec;21 Suppl 5:e106249. doi:[...]

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E,[...]

Intestinal Microbiome in Response to Air Pollutant Exposure in Pregestational and Gestational Murine Females and their Male and Female Offspring

Ghosh S, Ganguly A, Dong TS, Lagishetty V, Jacobs JP, Devaskar SU. Intestinal Microbiome in Response to Air Pollutant Exposure in Pregestational and Gestational Murine[...]